UCB BIOPHARMA earnings
Annual earnings per share (EUR per share, as reported)
| Fiscal year | Period end | Diluted EPS | Basic EPS | Filed |
|---|---|---|---|---|
| 2022 | 2022-12-31 | €2.14 | €2.20 | 2026-06-19T05:50:29Z |
| 2021 | 2021-12-31 | €5.45 | €5.60 | 2026-06-19T05:50:29Z |
Revenue & profit (EUR)
| Concept | 2022 | 2021 |
|---|---|---|
| Revenue | €5.52B | €5.78B |
| Profit for the year | €418.0M | €1.06B |
Methodology
Earnings per share comes from ifrs-full:DilutedEarningsLossPerShare /
ifrs-full:BasicEarningsLossPerShare; revenue from
ifrs-full:Revenue and profit from ifrs-full:ProfitLoss,
as tagged in UCB BIOPHARMA's ESEF annual reports (source:
filings.xbrl.org).
Figures are in EUR, as reported. Not investment advice.